1. Home
  2. MEIP vs PT Comparison

MEIP vs PT Comparison

Compare MEIP & PT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • PT
  • Stock Information
  • Founded
  • MEIP 2000
  • PT 2012
  • Country
  • MEIP United States
  • PT China
  • Employees
  • MEIP 28
  • PT N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • PT Computer Software: Programming Data Processing
  • Sector
  • MEIP Health Care
  • PT Technology
  • Exchange
  • MEIP Nasdaq
  • PT Nasdaq
  • Market Cap
  • MEIP 17.3M
  • PT 15.2M
  • IPO Year
  • MEIP 2003
  • PT 2018
  • Fundamental
  • Price
  • MEIP $2.60
  • PT $1.04
  • Analyst Decision
  • MEIP Hold
  • PT
  • Analyst Count
  • MEIP 2
  • PT 0
  • Target Price
  • MEIP $7.00
  • PT N/A
  • AVG Volume (30 Days)
  • MEIP 7.5K
  • PT 30.7K
  • Earning Date
  • MEIP 02-12-2025
  • PT 11-08-2024
  • Dividend Yield
  • MEIP N/A
  • PT N/A
  • EPS Growth
  • MEIP N/A
  • PT N/A
  • EPS
  • MEIP N/A
  • PT N/A
  • Revenue
  • MEIP N/A
  • PT $4,479,352.00
  • Revenue This Year
  • MEIP N/A
  • PT N/A
  • Revenue Next Year
  • MEIP N/A
  • PT N/A
  • P/E Ratio
  • MEIP N/A
  • PT N/A
  • Revenue Growth
  • MEIP 33.76
  • PT N/A
  • 52 Week Low
  • MEIP $2.30
  • PT $0.71
  • 52 Week High
  • MEIP $4.42
  • PT $1.25
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 37.79
  • PT 55.60
  • Support Level
  • MEIP $2.55
  • PT $0.93
  • Resistance Level
  • MEIP $2.79
  • PT $1.15
  • Average True Range (ATR)
  • MEIP 0.14
  • PT 0.06
  • MACD
  • MEIP -0.02
  • PT 0.01
  • Stochastic Oscillator
  • MEIP 14.71
  • PT 57.69

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees also by providing financing for these borrowers and earn installment service fees, They earn wealth management services fees and commission on financial products.

Share on Social Networks: